We found that with the increasing rates of the AST/ALT level (Q1 14.97%, Q2 32.89%, Q3 56.55% and Q4 86.21%), the prevalence of osteopenia/osteoporosis increased progressively in T2DM patients (Fig. 2). This evidence concerns the gene GPT and Osteopenia.